FDA Approvals

FDA Approves Decnupaz for Rare Blood Cancer

The approval gives adults with blastic plasmacytoid dendritic cell neoplasm a second CD123‑targeted treatment backed by CADENZA response data, with a boxed warning for serious liver toxicity.